WHOOP Unveils WHOOP® 5.0 and WHOOP® MG: Powerful New Devices with Breakthrough Health and Longevity Features
BOSTON--(BUSINESS WIRE)-- WHOOP, the human performance company, today introduces WHOOP 5.0 and WHOOP MG — two next-generation wearables designed to unlock a new approach to personal health and longevity. Paired with a redesigned WHOOP experience, the devices offer 14-day battery life in a sleeker, seven percent smaller form - and introduce category-defining features, including Healthspan with WHOOP Age, Heart Screener with on-demand ECG, Blood Pressure Insights, and more.
These innovations arrive at a pivotal moment when ailing health systems cost more and deliver less. WHOOP is advancing a new solution and a better way - one that empowers people to connect their daily decisions to performance and health outcomes that can be measured and felt. While others track surface-level trends, WHOOP delivers longevity through depth — translating the body's most vital signals into guidance that extends healthspan, not just lifespan.
'This isn't just a product launch. It's a new chapter for WHOOP and for our members,' said Will Ahmed, WHOOP Founder & CEO. 'We've taken everything we've learned over the past decade and built a platform to help our members perform and live at their peak for longer. We've held nothing back.'
Imagery of WHOOP 5.0 and WHOOP MG h ere.
NEW HEALTH AND PERFORMANCE IN-APP FEATURES:
Healthspan with WHOOP Age 1: Get insights and guidance on how your daily habits impact your long-term health with Healthspan - a powerful new way to quantify your physiological age and slow your Pace of Aging. Developed in partnership with Dr. Eric Verdin, CEO of the Buck Institute for Research on Aging, Healthspan uses nine different metrics linked to long-term health to calculate your WHOOP Age and Pace of Aging.
Heart Screener with ECG 2: Your heart, in your hands. WHOOP now includes an FDA-cleared ECG feature that allows a reading to be taken anytime, from your wrist — and shared directly with a healthcare provider. The Heart Screener detects signs of Atrial Fibrillation (Afib) 3, a leading cause of stroke, and provides Irregular Heart Rhythm Notifications 4 (IHRN) for greater peace of mind.
Blood Pressure Insights 5: A patent-pending technology that delivers daily blood pressure insights, right from your wrist. Get estimated systolic and diastolic readings, and learn about how blood pressure affects wellbeing and performance.
Women's Hormonal Insights 6: WHOOP goes beyond cycle tracking to deliver science-backed education and personalized insights on how hormonal shifts influence recovery, sleep, stress and performance. Whether you're navigating menstruation, pregnancy, or perimenopause — WHOOP adapts with you.
Sleep Performance Update: Unlock better nights and better days. The reimagined Sleep Score delivers a more accurate reflection of sleep quality, helping members recover more effectively and show up stronger each day.
WHOOP Advanced Labs 7: Join the waitlist for the next evolution in personalized health. Coming soon, WHOOP Advanced Labs will allow members to schedule blood tests and receive clinician reports that are integrated directly into the WHOOP app, creating a more comprehensive picture of your health — and giving you actionable steps to improve it.
Comprehensive Fitness Tracking: From daily steps and VO₂ Max to Muscular Strain during strength training and 145+ supported activities, members can now optimize fitness for both performance and long-term health outcomes.
HARDWARE, REIMAGINED FOR PERFORMANCE AND PRECISION:
Precision Sensors. Smaller Design. Greater Power: WHOOP 5.0 and MG pack more technology into a seven percent smaller form factor. Enhanced sensors capture data 26 times per second, while a redesigned processor delivers 10x more power efficiency — enabling richer insights without sacrificing battery life or comfort.
14+ Day Battery Life. New Wireless PowerPack 8: 14+ days per charge across WHOOP 5.0 and MG hardware. Now, members with their device alongside the new Wireless Powerpack have access to a full month of battery life.
Elevated Accessories: Complete the experience with a new line of WHOOP accessories — including the new LeatherLuxe, crafted from genuine Italian leather for our most premium look and feel yet.
24/7 Wearability: WHOOP remains the only wearable that's truly wearable — designed for 24/7 use across multiple locations on the body. Powered by WHOOP Body and AnyWear™ technology, our technical garments seamlessly integrate with your device to capture data with unmatched precision — no matter your sport, lifestyle or movement.
Medical-Grade ECG: Available exclusively on WHOOP MG, maintain peace of mind with medical-grade ECG readings you can do from the comfort of home. Simply place your thumb and index finger on the ECG-conductive clasp, and get a medical-grade reading in seconds.
CHOOSE YOUR EXPERIENCE:
To make these innovations even more accessible, WHOOP is also introducing three new membership tiers. These tiers empower WHOOP members to choose the hardware device, features and pricing that make the most sense for them:
WHOOP One: Professional-grade fitness insights at our best price at $199 per year
WHOOP Peak: Advanced health, fitness and longevity insights designed to help you perform at your peak, longer. Priced at $239 per year
WHOOP Life: The most powerful WHOOP ever, delivering medical-grade health and performance insights. Priced at $359 per year
See below for global pricing.
'WHOOP is a great tool. It's like a doctor on my wrist,' said Cristiano Ronaldo, Professional Soccer Player and WHOOP Global Ambassador and Investor. 'It allows me to monitor my behavior easily, and shows me that being consistent and prioritizing your health is worth it. I'm happy to be part of this company, and the launch of the WHOOP 5.0 and MG.'
WHOOP 5.0 and MG are available to purchase now on WHOOP.com.
Global Pricing
About WHOOP
WHOOP, the human performance company, offers a wearable health and fitness coach to help people achieve their goals. The WHOOP membership provides best-in-class wearable technology, actionable feedback, and recommendations across recovery, sleep, training, and health. WHOOP 5.0 and WHOOP MG offer groundbreaking health innovations, including cardiovascular health features; Healthspan which quantifies Pace of Aging and provides members with their WHOOP Age; and first-of-its-kind wearable Blood Pressure Insights. WHOOP is the perfect health companion for anyone looking to optimize their health and performance. Founded in 2012, WHOOP is based in Boston and has raised more than $400 million in venture capital. WHOOP is available to ship in 56 markets worldwide and the WHOOP app is available in English, French, German, Italian and Spanish (Latin America). WHOOP can be purchased on Amazon across the U.S., U.K., and Australia, as well as Best Buy (U.S.) Dick's Sporting Goods (U.S.), Flipkart (India) and Virgin Megastore (GCC), and more.
To learn more or start a one-month free trial, visit whoop.com and connect with WHOOP on Instagram, X, Facebook, LinkedIn, and YouTube.
_________________________________
1 This feature is not available for users under the age of 18.
2 This feature is not intended for users with known arrhythmias other than AFib or users under 22 years old. It is not recommended for users with a cardiac pacemaker, ICDs or other implanted electronic devices. This is a medically regulated feature and is not currently available in every region.
3 https://pubmed.ncbi.nlm.nih.gov/33516402/
4 This feature is not intended for users with known atrial fibrillation or users under 22 years old. This is a medically regulated feature and is not currently available in every region.
5 Blood Pressure Monitor is not a medical device and cannot diagnose or manage medical conditions. It does not provide medical advice. Always consult your doctor for health concerns and never delay or modify medical care based on its information.
6 Menstrual Cycle Insights should not be used for birth control or fertility tracking. The ovulatory phase indicators are estimates only. Menstrual Cycle Insights is not a medical device and cannot diagnose or manage medical conditions. It does not provide medical advice. Always consult your doctor for health concerns and never delay or modify medical care based on its information.
7 USA only at launch.
8 Wireless PowerPack is offered with Peak & Life Memberships. Wired battery pack available on One.
Expand
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fox News
34 minutes ago
- Fox News
Cannabis
Cannabis is a drug that comes from the dried leaves, flowers, stems, and seeds of a cannabis sativa plant. Cannabis is commonly referred to as weed or marijuana, though marijuana refers to a specific part of the cannabis plant that contains high amounts of the psychoactive compound THC (tetrahydrocannabinol), which has mind-altering effects. CBD (cannabidiol) is another compound found in cannabis. In a single year, 52.5 million people in the United States use cannabis at least once, according to 2021 data from the Centers for Disease Control and Prevention (CDC). Cannabis has a direct effect on the brain, specifically the parts used for learning, decision-making, emotion, memory, reaction time, coordination, and attention, the CDC states. Marijuana is commonly smoked for recreational purposes. There are few prescription cannabis drugs approved by the Food and Drug Administration (FDA) for medicinal purposes. One example is Epidiolex, which is used to treat seizures. The legalization of marijuana is a varying issue on a state-by-state basis. Some states have legalized marijuana for medicinal purposes, while in others marijuana is legal for both recreational and medicinal purposes. Idaho, Kansas, South Carolina and Wyoming are the only states where marijuana is fully illegal.
Yahoo
an hour ago
- Yahoo
Ascletis Announces Phase III Trial of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne, Meets All Endpoints
Denifanstat (ASC40), a once-daily oral fatty acid synthase (FASN) inhibitor, demonstrated statistically significant and clinically meaningful improvement compared to placebo in all primary, key secondary, and secondary endpoints Denifanstat demonstrated a favorable safety and tolerability profile Denifanstat was 98% and 178% more effective than U.S. Food and Drug Administration (FDA)-approved sarecycline and doxycycline with regard to placebo-adjusted percent treatment success, respectively, 18.6% for denifanstat versus 9.4% for sarecycline, 18.6% versus 6.7% for doxycycline Denifanstat was 60% more effective than FDA-approved clascoterone cream with regard to placebo-adjusted percent treatment success, 18.6% for denifanstat versus 11.6% for clascoterone cream, respectively The exceptional efficacy of denifanstat coupled with its favorable safety profile in the Phase III trial provides a potential major break-through for the treatment of acne HONG KONG, June 3, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that denifanstat (ASC40), a first-in-class, once-daily oral small molecule fatty acid synthase (FASN) inhibitor, meets all primary, key secondary, and secondary endpoints in the Phase III clinical trial for the treatment of moderate to severe acne vulgaris (NCT06192264). The Phase III clinical trial was a randomized, double-blind, placebo-controlled, multicenter clinical trial in China to evaluate the safety and efficacy of denifanstat once-daily oral tablet in 480 patients with moderate to severe acne vulgaris. Patients were enrolled and randomized into one active treatment arm and one placebo control arm at the ratio of 1:1 to receive 50 mg denifanstat oral tablet once daily or matching placebo for 12 weeks. Baseline characteristics were well balanced between denifanstat and placebo arms. Table 1 summarizes some of baseline characteristics. Primary, key secondary, and secondary endpoints can be found in Table 2. Primary endpoints included the percent treatment success (defined as an Investigator's Global Assessment (IGA) score of 0 (clear) or 1 (almost clear) with at least a 2-point decrease in IGA from baseline at week 12), the percent reduction from baseline in total lesion count, and the percent reduction from baseline in inflammatory lesion count. At week 12, percent treatment success was 33.2% compared to 14.6% for placebo, p<0.0001, percent reduction from baseline in total lesion count was 57.4% compared to 35.4% for placebo, p<0.0001, and percent reduction from baseline in inflammatory lesion count was 63.5% compared to 43.2% for placebo, p<0.0001. The key secondary endpoint, percent reduction from baseline in non-inflammatory lesion count at week 12, was 51.9% compared to 28.9% for placebo, p<0.0001. Denifanstat demonstrated a favorable safety and tolerability profile following 12 weeks of once-daily oral administration at 50 mg. The incidence rates of treatment-emergent adverse events (TEAEs) were comparable between denifanstat and placebo. No incidence rates of TEAEs related to study drug in any category exceeded 10%. Only two categories of TEAEs had an incidence rate of more than 5% (6.3% dry skin in denifanstat-treated patients versus 2.9% in the placebo group; 5.9% dry eye in denifanstat-treated patients versus 3.8% in the placebo group). All denifanstat-related adverse events (AEs) were mild or moderate. There were no denifanstat-related grade 3 or 4 AEs and no denifanstat-related serious AEs (SAEs). No deaths were reported. The mechanisms of action of denifanstat for the treatment of acne are (1) direct inhibition of facial sebum production, through inhibition of de novo lipogenesis (DNL) in human sebocytes; and (2) inhibition of inflammation, through decreasing cytokine secretion and Th17 differentiation. Denifanstat's unique mechanism of action directly reduces one of the main underlying causes of acne which is the overproduction of sebum. This makes denifanstat unique as most other acne treatments do not treat the underlying cause of the condition. "We are extremely pleased with the topline results of our Phase III trial. Denifanstat tablets demonstrated impressive efficacy beyond treatment success, showing significant reductions in total lesion count, inflammatory lesion count, and non-inflammatory lesion count. We are excited to be submitting this innovative treatment with the China National Medical Products Administration (NMPA) soon." said Jinzi Jason Wu, Ph.D., Founder, Chairman and CEO of Ascletis. Table 3 highlights the excellent efficacy of denifanstat in a non-head-to-head comparison to other commonly used oral and topical acne treatments. Denifanstat demonstrated its exceptional efficacy across multiple key metrics compared to sarecycline, doxycycline and clascoterone cream. With regard to the placebo-adjusted percent treatment success and the placebo-adjusted percent reduction from baseline in inflammatory lesion count, denifanstat was 98% and 30% more effective than sarecycline, respectively, 178% and 178% more effective than doxycycline, respectively, and 60% and 59% more effective than clascoterone cream, respectively. With regard to the placebo-adjusted percent reduction from baseline in total lesion count, denifanstat was 189% and 85% more effective than doxycycline and clascoterone cream, respectively. With regard to the placebo-adjusted percent reduction from baseline in non-inflammatory lesion count, denifanstat was 411% and 102% more effective than sarecycline and clascoterone cream, respectively. Denifanstat has the potential to be a first-in-class, once-daily, oral acne therapeutic, potentially offering both exceptional efficacy and patient compliance with a favorable safety and tolerability profile. Compared to other oral acne treatments, denifanstat provides outstanding efficacy with excellent safety. There is no potential for antibiotic resistance or off target effects which can occur with tetracycline derivatives and no reported denifanstat-related severe AEs such as hepatotoxicity, hearing impairment and depression which are seen with isotretinoin. Denifanstat should also provide better adherence to treatment compared to topical therapies: an estimated 30% to 40% of patients do not adhere to their topical treatments[1]. Denifanstat is licensed from Sagimet Biosciences Inc. (Nasdaq: SGMT) for exclusive rights in Greater China. "The Phase III clinical trial results for denifanstat are highly encouraging. The data demonstrate statistically significant improvements in treatment outcomes for moderate-to-severe acne patients, with percent treatment success of 33.2%, total lesion count reduction of 57.4% from baseline, inflammatory and non-inflammatory lesion counts decreasing by 63.5% and 51.9%, respectively, while maintaining a favorable safety and tolerability profile. Denifanstat's first-in-class mechanism targeting FASN directly addresses a key cause for acne, establishing it as a groundbreaking therapeutic approach in acne treatment." said Prof. Leihong Xiang, Chief Physician of Dermatological Department, Huashan Hospital, Fudan University, Executive Deputy Director of Institute of Dermatology, Fudan University, Deputy Director of Dermatology Division of Chinese Medical Doctor Association and principal investigator of denifanstat Phase III trial for moderate to severe acne. [1] Purvis CG, Balogh EA, Feldman SR. Clascoterone: How the Novel Androgen Receptor Inhibitor Fits Into the Acne Treatment Paradigm. Ann Pharmacother. 2021;55(10):1297-1299. doi:10.1177/1060028021992055. Table 1. Baseline characteristics of Phase III trial of denifanstat Baseline characteristics 50 mg denifanstat, oral, oncedaily (n=240) Placebo, oral, once daily (n=240) Total lesion count 102.2 102.1 Inflammatory lesion count 42.1 43.1 IGA=3 (moderate), % 85.8 85.8 IGA=4 (severe), % 14.2 14.2 Table 2. Efficacy endpoints of 50 mg denifanstat oral, once daily at week 12 versus placebo (intent-to-treat, ITT, analysis) Efficacy endpoints (1) 50 mg denifanstat, oral, once daily (n=240) Placebo, oral,once daily (n=240) Placebo adjusted p value Percent treatment success (2) (primary endpoint) 33.2 14.6 18.6 <0.0001 Percent reduction from baseline in total lesion count (primary endpoint) 57.4 35.4 22.0 <0.0001 Percent reduction from baseline ininflammatory lesion count (primary endpoint) 63.5 43.2 20.3 <0.0001 Percent reduction from baseline in non-inflammatory lesion count (key secondary endpoint) 51.9 28.9 23.0 <0.0001 Absolute reduction from baseline intotal lesion count (secondary endpoint) 58.3 36.2 22.1 <0.0001 Absolute reduction from baseline in inflammatory lesion count (secondaryendpoint) 26.6 18.4 8.2 <0.0001 Notes: (1) All efficacy endpoints are least square means.(2) Treatment success is defined as an Investigator's Global Assessment (IGA) score of 0 (clear) or 1 (almost clear) with at least a 2-point decrease in IGA from baseline at week 12. Table 3. Denifanstat compared to other commonly used acne treatments (not head-to-head comparison) Category Denifanstat (n=240) Sarecycline(1) (n=1002) Doxycycline(2) (n=216) Clascoterone cream(3) (n=722) Baseline characteristics Total lesion count 102.2 72.4 71.7 103.6 Inflammatory lesion count 42.1 30.0 33.6 42.7 IGA=3 (moderate), % 85.8 85.2 93.5 82.7 IGA=4 (severe), % 14.2 14.9 6.5 17.3 Efficacy endpoints at week 12 Placebo-adjusted percenttreatment success 18.6 9.4 6.7 11.6 Placebo-adjusted percent reductionfrom baseline in total lesion count 22.0 NA 7.6 11.9 Placebo-adjusted percent reductionfrom baseline in inflammatorylesion count 20.3 15.6 7.3 12.8 Placebo-adjusted percent reduction from baseline in non-inflammatorylesion count 23.0 4.5 NA 11.4 Notes: (1) The sarecycline data represent an analysis of its two Phase III clinical trials, with values expressed as means. The data are from Moore, A., et al., J Drugs Dermatol 2018 Vol. 17 Issue 9 Pages 987-996. The non- inflammatory lesion count data are from FDA ( The doxycycline data at week 16 are from Moore, A., et al., J Drugs Dermatol 2015 Vol. 14 Issue 6 Pages 581-6.(3) The clascoterone cream (1%) data represent an analysis of its two Phase III clinical trials, with values expressed as means. The data are from Hebert. A, et al., JAMA Dermatology 2020 Vol. 156 Issue 6, DOI: 10.1001/jamadermatol.2020.0465. About Ascletis Pharma Inc. Ascletis is an innovative R&D driven biotech listed on the Hong Kong Stock Exchange ( covering the entire value chain from discovery and development to GMP manufacturing. Led by a management team with deep expertise and a proven track record, Ascletis is focused on metabolic diseases by addressing unmet medical needs from a global perspective. Ascletis has multiple clinical stage drug candidates in its metabolic disease pipeline. For more information, please visit Contact: Peter VozzoICR Healthcare443-231-0505 (U.S.) Ascletis Pharma Inc. PR and IR teams+86-181-0650-9129 (China)pr@ ir@ View original content: SOURCE Ascletis Pharma Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
The FDA Just Upgraded a Recall On This Popular Breakfast Item To The Highest Level—Here's What to Know
The FDA Just Upgraded a Recall On This Popular Breakfast Item To The Highest Level—Here's What to Know originally appeared on Parade. You'd be surprised just how contentious a conversation about bagels can get. Sure, they might seem innocuous and like a relatively safe topic of discussion, but if you get the right people in the room, things can go south pretty quickly. Born and raised New Yorkers know a thing or two about where to get the best bagels and you better not even think about scooping out the insides like they do in LA. There are even rules about slicing, and according to some people the water in Jersey makes their bagels the best on the planet. Told you it was a minefield. 😋😋SIGN UP to get delicious recipes, handy kitchen hacks & more in our daily Pop Kitchen newsletter🍳🍔 Regardless of how you like your bagel—toasted, schmeared with cream cheese, buttered, or topped with lox—there's no denying that it's one of the greatest grab-and-go breakfasts known to mankind. It's filling and satiating leaving and can easily go from sweet to savory without skipping a beat. No matter what side of the bagel spectrum you fall on, we can all agree, life's sweeter with one in only thing that could possibly make us put the carby wonders down for good is if, by some chance, the unassuming doughy breakfast companion turned out to be hazardous to our health and the health of those around us. Unfortunately, in the case of Utah-based bagel company New Grains Gluten Free Bakery, it looks like that just might be the case. According to a recent filing by the FDA, the recall was issued due to the undeclared presence of eggs in four varieties of gluten-free bagels—cinnamon raisin, plain, blueberry, and multigrain. Approximately 100 units of each type were affected by the recall. The recall is listed as Class I, the highest threat level, due to the potential for serious and life-threatening allergic reactions if consumed by someone with an egg allergy. In addition to the bagels, the brand also included artisan white bread, multigrain bread, sourdough, and cinnamon raisin bread in the recall due to the same labeling issue. The products were distributed between April 4 and 21 under lot numbers 90-107 and were packaged in clear, vacuum-sealed plastic bags. A total of 250 units of each product were distributed to retail locations in Utah, so it seems that the recall is relatively insulated for now. While there have been no reported injuries or illnesses, it's best to avoid consumption if you happen to have purchased one of the affected products. Of course, yours truly isn't allergic to eggs, so I'll make sure to eat one for the both of us FDA Just Upgraded a Recall On This Popular Breakfast Item To The Highest Level—Here's What to Know first appeared on Parade on Jun 3, 2025 This story was originally reported by Parade on Jun 3, 2025, where it first appeared.
